[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fcIo_2SG0Bww6mNiwKvTHLPL7o8DXLn5I1U1CfKzoFSE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":85,"rows":92},"Karolinska University Hospital",[4],273,false,44,13,1559239,22,204,[14,17,20,22,25,28,30,32],{"name":15,"count":16},"Critical Illness",11,{"name":18,"count":19},"Breast Cancer",7,{"name":21,"count":19},"Anesthesia",{"name":23,"count":24},"Cystic Fibrosis",6,{"name":26,"count":27},"Malaria",5,{"name":29,"count":27},"Aortic Valve Stenosis",{"name":31,"count":27},"Surgery",{"name":33,"count":27},"Aortic Aneurysm",[35,40,45,50,55,60,65,70,75,80],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT00798070","Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients","2016-04","dtEC→dtT",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05172310","PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI","2024-06-30","68Ga-FAPI-46",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05649605","Early Mental Response - The EMRE Study","2025-12-30","Testosterone treatment",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT03137966","Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers","2025-12-31","Deferoxamine",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT05788679","A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS","2026-12","Azacitidine",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT04460352","Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer","2026-12-31","Carboplatin, paclitaxel",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT05900206","Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer","2027-04-30","Trastuzumab deruxtecan",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT06639191","[177Lu]Lu-AKIR001 First-in-human Study","2027-11-01","[177Lu]Lu-AKIR001",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT07424690","Catheter Ablation vs Conservative Care in Elderly Patients With Atrial Fibrillation","2031-11-01","Optimized Medical Therapy for Atrial Fibrillation",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT06051045","Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Chronic Hepatitis D Patients","2033-03","Bulevirtide",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,120,138,156,179,197,243,274,310,328,346,364,382,400,418,436,454,477,502,529,553,577,598,630,655,679,704,722,748,772,801,819,845,863,889,907,933,951,976,1001,1028,1046,1064,1090,1108,1135,1153,1171,1196,1223,1250,1273,1301,1319,1349,1375,1393,1416,1441,1466,1493,1511,1538,1556,1574,1603,1627,1652,1670,1697,1721,1739,1757,1775,1793,1821,1839,1867,1885,1909,1933,1958,1982,2009,2034,2060,2086,2109,2134,2158,2184,2202,2226,2250,2273,2297,2322,2344,2369,2394],{"intervention":64,"totalTrials":94,"cells":95},1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":116,"NA":118},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":94,"soonestReadout":63},[105],{"nctId":61,"briefTitle":62,"status":106,"phases":107,"primaryCompletion":63,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":113},"RECRUITING",[89],"2031-12-31","2020-11-27",1020,[112],"Esophageal Squamous Cell Carcinoma",[64,64,114,115],"Cisplatin, paclitaxel","Oxaliplatin, calcium folinate, 5-fluorouracil",{"trials":117,"activeCount":98},[],{"trials":119,"activeCount":98},[],{"intervention":114,"totalTrials":94,"cells":121},{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":128,"PHASE4":134,"NA":136},{"trials":123,"activeCount":98},[],{"trials":125,"activeCount":98},[],{"trials":127,"activeCount":98},[],{"trials":129,"activeCount":94,"soonestReadout":63},[130],{"nctId":61,"briefTitle":62,"status":106,"phases":131,"primaryCompletion":63,"completion":108,"start":109,"enrollment":110,"conditions":132,"interventions":133},[89],[112],[64,64,114,115],{"trials":135,"activeCount":98},[],{"trials":137,"activeCount":98},[],{"intervention":115,"totalTrials":94,"cells":139},{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":152,"NA":154},{"trials":141,"activeCount":98},[],{"trials":143,"activeCount":98},[],{"trials":145,"activeCount":98},[],{"trials":147,"activeCount":94,"soonestReadout":63},[148],{"nctId":61,"briefTitle":62,"status":106,"phases":149,"primaryCompletion":63,"completion":108,"start":109,"enrollment":110,"conditions":150,"interventions":151},[89],[112],[64,64,114,115],{"trials":153,"activeCount":98},[],{"trials":155,"activeCount":98},[],{"intervention":39,"totalTrials":94,"cells":157},{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":164,"PHASE4":175,"NA":177},{"trials":159,"activeCount":98},[],{"trials":161,"activeCount":98},[],{"trials":163,"activeCount":98},[],{"trials":165,"activeCount":94,"soonestReadout":38},[166],{"nctId":36,"briefTitle":37,"status":167,"phases":168,"primaryCompletion":38,"completion":169,"start":170,"enrollment":171,"conditions":172,"interventions":173},"ACTIVE_NOT_RECRUITING",[89],"2028-01","2007-02",2017,[18],[39,174],"FEC→T",{"trials":176,"activeCount":98},[],{"trials":178,"activeCount":98},[],{"intervention":174,"totalTrials":94,"cells":180},{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":193,"NA":195},{"trials":182,"activeCount":98},[],{"trials":184,"activeCount":98},[],{"trials":186,"activeCount":98},[],{"trials":188,"activeCount":94,"soonestReadout":38},[189],{"nctId":36,"briefTitle":37,"status":167,"phases":190,"primaryCompletion":38,"completion":169,"start":170,"enrollment":171,"conditions":191,"interventions":192},[89],[18],[39,174],{"trials":194,"activeCount":98},[],{"trials":196,"activeCount":98},[],{"intervention":198,"totalTrials":199,"cells":200},"Cyclophosphamide",2,{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":220,"PHASE3":237,"PHASE4":239,"NA":241},{"trials":202,"activeCount":98},[],{"trials":204,"activeCount":98},[205],{"nctId":206,"briefTitle":207,"status":208,"phases":209,"primaryCompletion":210,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":215},"NCT01946373","T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma","UNKNOWN",[87],"2025-12","2013-10",20,[214],"Melanoma",[198,216,217,218,219],"Fludarabine","T cells","Interleukin-2","Dendritic cell vaccine",{"trials":221,"activeCount":94,"soonestReadout":68},[222],{"nctId":66,"briefTitle":67,"status":106,"phases":223,"primaryCompletion":68,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":228},[88],"2032-04-30","2023-10-26",370,[18],[69,229,230,231,232,233,234,235,236,198],"Docetaxel","Paclitaxel","Carboplatin","Trastuzumab","Pertuzumab","Ribociclib","Letrozole","Epirubicin",{"trials":238,"activeCount":98},[],{"trials":240,"activeCount":98},[],{"trials":242,"activeCount":98},[],{"intervention":229,"totalTrials":199,"cells":244},{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":249,"PHASE3":268,"PHASE4":270,"NA":272},{"trials":246,"activeCount":98},[],{"trials":248,"activeCount":98},[],{"trials":250,"activeCount":94,"soonestReadout":68},[251,264],{"nctId":252,"briefTitle":253,"status":208,"phases":254,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":262},"NCT00821912","TaxXel: Taxotere and Xeloda in Esophageal Cancer",[87,88],"2012-09","2013-09","2006-03",93,[260,261],"Cancer of the Esophagus","Gastric Cardia Carcinoma",[229,263],"Capecitabine",{"nctId":66,"briefTitle":67,"status":106,"phases":265,"primaryCompletion":68,"completion":224,"start":225,"enrollment":226,"conditions":266,"interventions":267},[88],[18],[69,229,230,231,232,233,234,235,236,198],{"trials":269,"activeCount":98},[],{"trials":271,"activeCount":98},[],{"trials":273,"activeCount":98},[],{"intervention":59,"totalTrials":199,"cells":275},{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":304,"PHASE4":306,"NA":308},{"trials":277,"activeCount":98},[],{"trials":279,"activeCount":98},[],{"trials":281,"activeCount":94,"soonestReadout":58},[282,291],{"nctId":56,"briefTitle":57,"status":106,"phases":283,"primaryCompletion":58,"completion":58,"start":284,"enrollment":285,"conditions":286,"interventions":290},[88],"2022-11-22",200,[287,288,289],"Myelodysplastic Syndromes","Acute Myeloid Leukemia With Myelodysplasia Related Disease and \u003C 30% Blasts","Mixed Myelodysplastic\u002FMyeloproliferative Disease",[59],{"nctId":292,"briefTitle":293,"status":294,"phases":295,"primaryCompletion":296,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":302},"NCT01794169","Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML","TERMINATED",[88],"2015-09","2018-03","2013-03",130,[301],"Acute Myeloid Leukemia",[59,303],"DA",{"trials":305,"activeCount":98},[],{"trials":307,"activeCount":98},[],{"trials":309,"activeCount":98},[],{"intervention":69,"totalTrials":94,"cells":311},{"EARLY_PHASE1":312,"PHASE1":314,"PHASE2":316,"PHASE3":322,"PHASE4":324,"NA":326},{"trials":313,"activeCount":98},[],{"trials":315,"activeCount":98},[],{"trials":317,"activeCount":94,"soonestReadout":68},[318],{"nctId":66,"briefTitle":67,"status":106,"phases":319,"primaryCompletion":68,"completion":224,"start":225,"enrollment":226,"conditions":320,"interventions":321},[88],[18],[69,229,230,231,232,233,234,235,236,198],{"trials":323,"activeCount":98},[],{"trials":325,"activeCount":98},[],{"trials":327,"activeCount":98},[],{"intervention":230,"totalTrials":94,"cells":329},{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":340,"PHASE4":342,"NA":344},{"trials":331,"activeCount":98},[],{"trials":333,"activeCount":98},[],{"trials":335,"activeCount":94,"soonestReadout":68},[336],{"nctId":66,"briefTitle":67,"status":106,"phases":337,"primaryCompletion":68,"completion":224,"start":225,"enrollment":226,"conditions":338,"interventions":339},[88],[18],[69,229,230,231,232,233,234,235,236,198],{"trials":341,"activeCount":98},[],{"trials":343,"activeCount":98},[],{"trials":345,"activeCount":98},[],{"intervention":231,"totalTrials":94,"cells":347},{"EARLY_PHASE1":348,"PHASE1":350,"PHASE2":352,"PHASE3":358,"PHASE4":360,"NA":362},{"trials":349,"activeCount":98},[],{"trials":351,"activeCount":98},[],{"trials":353,"activeCount":94,"soonestReadout":68},[354],{"nctId":66,"briefTitle":67,"status":106,"phases":355,"primaryCompletion":68,"completion":224,"start":225,"enrollment":226,"conditions":356,"interventions":357},[88],[18],[69,229,230,231,232,233,234,235,236,198],{"trials":359,"activeCount":98},[],{"trials":361,"activeCount":98},[],{"trials":363,"activeCount":98},[],{"intervention":232,"totalTrials":94,"cells":365},{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":376,"PHASE4":378,"NA":380},{"trials":367,"activeCount":98},[],{"trials":369,"activeCount":98},[],{"trials":371,"activeCount":94,"soonestReadout":68},[372],{"nctId":66,"briefTitle":67,"status":106,"phases":373,"primaryCompletion":68,"completion":224,"start":225,"enrollment":226,"conditions":374,"interventions":375},[88],[18],[69,229,230,231,232,233,234,235,236,198],{"trials":377,"activeCount":98},[],{"trials":379,"activeCount":98},[],{"trials":381,"activeCount":98},[],{"intervention":233,"totalTrials":94,"cells":383},{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":394,"PHASE4":396,"NA":398},{"trials":385,"activeCount":98},[],{"trials":387,"activeCount":98},[],{"trials":389,"activeCount":94,"soonestReadout":68},[390],{"nctId":66,"briefTitle":67,"status":106,"phases":391,"primaryCompletion":68,"completion":224,"start":225,"enrollment":226,"conditions":392,"interventions":393},[88],[18],[69,229,230,231,232,233,234,235,236,198],{"trials":395,"activeCount":98},[],{"trials":397,"activeCount":98},[],{"trials":399,"activeCount":98},[],{"intervention":234,"totalTrials":94,"cells":401},{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":406,"PHASE3":412,"PHASE4":414,"NA":416},{"trials":403,"activeCount":98},[],{"trials":405,"activeCount":98},[],{"trials":407,"activeCount":94,"soonestReadout":68},[408],{"nctId":66,"briefTitle":67,"status":106,"phases":409,"primaryCompletion":68,"completion":224,"start":225,"enrollment":226,"conditions":410,"interventions":411},[88],[18],[69,229,230,231,232,233,234,235,236,198],{"trials":413,"activeCount":98},[],{"trials":415,"activeCount":98},[],{"trials":417,"activeCount":98},[],{"intervention":235,"totalTrials":94,"cells":419},{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":430,"PHASE4":432,"NA":434},{"trials":421,"activeCount":98},[],{"trials":423,"activeCount":98},[],{"trials":425,"activeCount":94,"soonestReadout":68},[426],{"nctId":66,"briefTitle":67,"status":106,"phases":427,"primaryCompletion":68,"completion":224,"start":225,"enrollment":226,"conditions":428,"interventions":429},[88],[18],[69,229,230,231,232,233,234,235,236,198],{"trials":431,"activeCount":98},[],{"trials":433,"activeCount":98},[],{"trials":435,"activeCount":98},[],{"intervention":236,"totalTrials":94,"cells":437},{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":442,"PHASE3":448,"PHASE4":450,"NA":452},{"trials":439,"activeCount":98},[],{"trials":441,"activeCount":98},[],{"trials":443,"activeCount":94,"soonestReadout":68},[444],{"nctId":66,"briefTitle":67,"status":106,"phases":445,"primaryCompletion":68,"completion":224,"start":225,"enrollment":226,"conditions":446,"interventions":447},[88],[18],[69,229,230,231,232,233,234,235,236,198],{"trials":449,"activeCount":98},[],{"trials":451,"activeCount":98},[],{"trials":453,"activeCount":98},[],{"intervention":54,"totalTrials":94,"cells":455},{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":471,"PHASE4":473,"NA":475},{"trials":457,"activeCount":98},[],{"trials":459,"activeCount":98},[],{"trials":461,"activeCount":94,"soonestReadout":53},[462],{"nctId":51,"briefTitle":52,"status":463,"phases":464,"primaryCompletion":53,"completion":465,"start":466,"enrollment":467,"conditions":468,"interventions":470},"NOT_YET_RECRUITING",[88],"2026-06-30","2022-12-30",174,[469],"Diabetic Foot Ulcer",[54],{"trials":472,"activeCount":98},[],{"trials":474,"activeCount":98},[],{"trials":476,"activeCount":98},[],{"intervention":44,"totalTrials":94,"cells":478},{"EARLY_PHASE1":479,"PHASE1":481,"PHASE2":494,"PHASE3":496,"PHASE4":498,"NA":500},{"trials":480,"activeCount":98},[],{"trials":482,"activeCount":94,"soonestReadout":43},[483],{"nctId":41,"briefTitle":42,"status":106,"phases":484,"primaryCompletion":43,"completion":485,"start":486,"enrollment":487,"conditions":488,"interventions":493},[87],"2029-03-31","2021-06-02",410,[489,490,491,492],"Pancreatic Neoplasms","Stomach Neoplasms","Bile Duct Neoplasms","Epithelial Ovarian Cancer",[44],{"trials":495,"activeCount":98},[],{"trials":497,"activeCount":98},[],{"trials":499,"activeCount":98},[],{"trials":501,"activeCount":98},[],{"intervention":74,"totalTrials":94,"cells":503},{"EARLY_PHASE1":504,"PHASE1":519,"PHASE2":521,"PHASE3":523,"PHASE4":525,"NA":527},{"trials":505,"activeCount":94,"soonestReadout":73},[506],{"nctId":71,"briefTitle":72,"status":106,"phases":507,"primaryCompletion":73,"completion":508,"start":509,"enrollment":510,"conditions":511,"interventions":518},[86],"2028-11-01","2026-01-28",15,[512,513,514,515,516,517],"Thyroid Gland Anaplastic Carcinoma","Poorly Differentiated Thyroid Carcinoma","Cancer Head and Neck","Cervix Carcinoma","Vulvar Cancer, Stage IV","Non-small Cell Lung Cancer Stage IV",[74],{"trials":520,"activeCount":98},[],{"trials":522,"activeCount":98},[],{"trials":524,"activeCount":98},[],{"trials":526,"activeCount":98},[],{"trials":528,"activeCount":98},[],{"intervention":79,"totalTrials":94,"cells":530},{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":537,"PHASE4":539,"NA":541},{"trials":532,"activeCount":98},[],{"trials":534,"activeCount":98},[],{"trials":536,"activeCount":98},[],{"trials":538,"activeCount":98},[],{"trials":540,"activeCount":98},[],{"trials":542,"activeCount":94,"soonestReadout":78},[543],{"nctId":76,"briefTitle":77,"status":463,"phases":544,"primaryCompletion":78,"completion":545,"start":546,"enrollment":547,"conditions":548,"interventions":552},[91],"2034-09-01","2026-05-20",282,[549,550,551],"Atrial Fibrillation (AF)","Atrial Fibrillation Ablation","Elderly",[79],{"intervention":49,"totalTrials":94,"cells":554},{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":559,"PHASE3":561,"PHASE4":563,"NA":565},{"trials":556,"activeCount":98},[],{"trials":558,"activeCount":98},[],{"trials":560,"activeCount":98},[],{"trials":562,"activeCount":98},[],{"trials":564,"activeCount":98},[],{"trials":566,"activeCount":94,"soonestReadout":48},[567],{"nctId":46,"briefTitle":47,"status":106,"phases":568,"primaryCompletion":48,"completion":569,"start":570,"enrollment":571,"conditions":572,"interventions":576},[91],"2026-12-30","2023-03-07",70,[573,574,575],"Gender Dysphoria","Gender Identity","Gender Issues",[49],{"intervention":84,"totalTrials":94,"cells":578},{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":583,"PHASE3":585,"PHASE4":587,"NA":589},{"trials":580,"activeCount":98},[],{"trials":582,"activeCount":98},[],{"trials":584,"activeCount":98},[],{"trials":586,"activeCount":98},[],{"trials":588,"activeCount":98},[],{"trials":590,"activeCount":94,"soonestReadout":83},[591],{"nctId":81,"briefTitle":82,"status":106,"phases":592,"primaryCompletion":83,"completion":83,"start":593,"enrollment":594,"conditions":595,"interventions":597},[],"2023-09-27",400,[596],"Chronic Hepatitis D",[84],{"intervention":599,"totalTrials":199,"cells":600},"artemether-lumefantrine",{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":609,"NA":628},{"trials":602,"activeCount":98},[],{"trials":604,"activeCount":98},[],{"trials":606,"activeCount":98},[],{"trials":608,"activeCount":98},[],{"trials":610,"activeCount":98},[611,619],{"nctId":612,"briefTitle":613,"status":614,"phases":615,"start":616,"enrollment":285,"conditions":617,"interventions":618},"NCT00454961","Effectiveness of Artemether-Lumefantrine for Malaria Treatment of Children at Community Level in Tanzania","COMPLETED",[90],"2007-04",[26],[599],{"nctId":620,"briefTitle":621,"status":614,"phases":622,"completion":623,"start":624,"enrollment":625,"conditions":626,"interventions":627},"NCT00336375","Treatment of Uncomplicated Childhood Malaria in Tanzania by Artemether+Lumefantrine - Efficacy and Genotyping",[90],"2006-07","2006-06",50,[26],[599],{"trials":629,"activeCount":98},[],{"intervention":631,"totalTrials":94,"cells":632},"Acetylcysteine",{"EARLY_PHASE1":633,"PHASE1":635,"PHASE2":637,"PHASE3":639,"PHASE4":641,"NA":653},{"trials":634,"activeCount":98},[],{"trials":636,"activeCount":98},[],{"trials":638,"activeCount":98},[],{"trials":640,"activeCount":98},[],{"trials":642,"activeCount":98},[643],{"nctId":644,"briefTitle":645,"status":614,"phases":646,"primaryCompletion":647,"completion":647,"start":648,"enrollment":649,"conditions":650,"interventions":652},"NCT00525551","Efficacy of Acetylcysteine in Patients Undergoing Surgery for Otosclerosis",[90],"2013-04","2007-09",152,[651],"Otosclerosis",[631],{"trials":654,"activeCount":98},[],{"intervention":656,"totalTrials":94,"cells":657},"artesunate + amodiaquine",{"EARLY_PHASE1":658,"PHASE1":660,"PHASE2":662,"PHASE3":664,"PHASE4":666,"NA":677},{"trials":659,"activeCount":98},[],{"trials":661,"activeCount":98},[],{"trials":663,"activeCount":98},[],{"trials":665,"activeCount":98},[],{"trials":667,"activeCount":98},[668],{"nctId":669,"briefTitle":670,"status":671,"phases":672,"start":673,"enrollment":674,"conditions":675,"interventions":676},"NCT00465257","Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction in Zanzibar","SUSPENDED",[90],"2007-05",110,[26],[656],{"trials":678,"activeCount":98},[],{"intervention":680,"totalTrials":94,"cells":681},"methadone",{"EARLY_PHASE1":682,"PHASE1":684,"PHASE2":686,"PHASE3":688,"PHASE4":690,"NA":702},{"trials":683,"activeCount":98},[],{"trials":685,"activeCount":98},[],{"trials":687,"activeCount":98},[],{"trials":689,"activeCount":98},[],{"trials":691,"activeCount":98},[692],{"nctId":693,"briefTitle":694,"status":614,"phases":695,"completion":257,"start":696,"enrollment":697,"conditions":698,"interventions":700},"NCT00310934","A Stepwise Strategy Utilizing Buprenorphine and Methadone",[90],"2005-08",96,[699],"Heroin Dependence",[680,701],"buprenorphine \u002F methadone sequence",{"trials":703,"activeCount":98},[],{"intervention":701,"totalTrials":94,"cells":705},{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":710,"PHASE3":712,"PHASE4":714,"NA":720},{"trials":707,"activeCount":98},[],{"trials":709,"activeCount":98},[],{"trials":711,"activeCount":98},[],{"trials":713,"activeCount":98},[],{"trials":715,"activeCount":98},[716],{"nctId":693,"briefTitle":694,"status":614,"phases":717,"completion":257,"start":696,"enrollment":697,"conditions":718,"interventions":719},[90],[699],[680,701],{"trials":721,"activeCount":98},[],{"intervention":723,"totalTrials":94,"cells":724},"Comirnaty",{"EARLY_PHASE1":725,"PHASE1":727,"PHASE2":729,"PHASE3":731,"PHASE4":733,"NA":746},{"trials":726,"activeCount":98},[],{"trials":728,"activeCount":98},[],{"trials":730,"activeCount":98},[],{"trials":732,"activeCount":98},[],{"trials":734,"activeCount":98},[735],{"nctId":736,"briefTitle":737,"status":614,"phases":738,"primaryCompletion":739,"completion":740,"start":741,"enrollment":742,"conditions":743,"interventions":745},"NCT04780659","COVID-19 Vaccination of Immunodeficient Persons (COVAXID)",[90],"2021-10-15","2024-05-08","2021-02-23",539,[744],"Covid19",[723],{"trials":747,"activeCount":98},[],{"intervention":749,"totalTrials":94,"cells":750},"Candesartan",{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":757,"PHASE4":759,"NA":770},{"trials":752,"activeCount":98},[],{"trials":754,"activeCount":98},[],{"trials":756,"activeCount":98},[],{"trials":758,"activeCount":98},[],{"trials":760,"activeCount":98},[761],{"nctId":762,"briefTitle":763,"status":208,"phases":764,"completion":765,"start":766,"enrollment":9,"conditions":767,"interventions":769},"NCT00328302","Diabetes Type 1, Treatment Study Atacand\u002FPlacebo After Kidney Biopsy",[90],"2006-04","2000-09",[768],"Diabetes, Type I",[749],{"trials":771,"activeCount":98},[],{"intervention":773,"totalTrials":94,"cells":774},"Methylnaltrexone bromide (Relistor®).",{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":781,"PHASE4":783,"NA":799},{"trials":776,"activeCount":98},[],{"trials":778,"activeCount":98},[],{"trials":780,"activeCount":98},[],{"trials":782,"activeCount":98},[],{"trials":784,"activeCount":98},[785],{"nctId":786,"briefTitle":787,"status":614,"phases":788,"primaryCompletion":789,"completion":789,"start":790,"enrollment":791,"conditions":792,"interventions":797},"NCT02942550","Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients",[90],"2017-12","2016-11",82,[793,794,795,796],"STEMI","Morphine","Ticagrelor","Methylnaltrexone",[773,798],"Sodium Chloride 9mg\u002FmL",{"trials":800,"activeCount":98},[],{"intervention":798,"totalTrials":94,"cells":802},{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":807,"PHASE3":809,"PHASE4":811,"NA":817},{"trials":804,"activeCount":98},[],{"trials":806,"activeCount":98},[],{"trials":808,"activeCount":98},[],{"trials":810,"activeCount":98},[],{"trials":812,"activeCount":98},[813],{"nctId":786,"briefTitle":787,"status":614,"phases":814,"primaryCompletion":789,"completion":789,"start":790,"enrollment":791,"conditions":815,"interventions":816},[90],[793,794,795,796],[773,798],{"trials":818,"activeCount":98},[],{"intervention":820,"totalTrials":94,"cells":821},"Calendula Weleda cream (Weleda AG, Sweden) contains extracts of marigold plant (Calendula Officinalis 10%), wool fat and sesame oil",{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":828,"PHASE4":841,"NA":843},{"trials":823,"activeCount":98},[],{"trials":825,"activeCount":98},[],{"trials":827,"activeCount":98},[],{"trials":829,"activeCount":98},[830],{"nctId":831,"briefTitle":832,"status":614,"phases":833,"primaryCompletion":834,"completion":255,"start":835,"enrollment":836,"conditions":837,"interventions":839},"NCT01688479","Trial Comparing Calendula Officinalis With Aqueous Cream \"Essex\" to Treat Skin Reactions From Radiotherapy of Breast Cancer",[89],"2012-03","2011-02",420,[838],"Postoperative Radiotherapy Breast Cancer",[820,840],"Essex® cream (Schering-Plough), aqueous cream without parabens",{"trials":842,"activeCount":98},[],{"trials":844,"activeCount":98},[],{"intervention":840,"totalTrials":94,"cells":846},{"EARLY_PHASE1":847,"PHASE1":849,"PHASE2":851,"PHASE3":853,"PHASE4":859,"NA":861},{"trials":848,"activeCount":98},[],{"trials":850,"activeCount":98},[],{"trials":852,"activeCount":98},[],{"trials":854,"activeCount":98},[855],{"nctId":831,"briefTitle":832,"status":614,"phases":856,"primaryCompletion":834,"completion":255,"start":835,"enrollment":836,"conditions":857,"interventions":858},[89],[838],[820,840],{"trials":860,"activeCount":98},[],{"trials":862,"activeCount":98},[],{"intervention":864,"totalTrials":94,"cells":865},"NutropinAq",{"EARLY_PHASE1":866,"PHASE1":868,"PHASE2":870,"PHASE3":872,"PHASE4":885,"NA":887},{"trials":867,"activeCount":98},[],{"trials":869,"activeCount":98},[],{"trials":871,"activeCount":98},[],{"trials":873,"activeCount":98},[874],{"nctId":875,"briefTitle":876,"status":614,"phases":877,"primaryCompletion":878,"completion":878,"start":879,"enrollment":880,"conditions":881,"interventions":883},"NCT01020955","Metabolic Effects of GH and IGF-I in Growth Hormone Deficient(GHD) and Diabetes and Impaired Glucose Tolerance(IGT)",[89],"2011-11","2009-10",14,[882],"Diabetes",[864,884],"NutropinAq and placebo",{"trials":886,"activeCount":98},[],{"trials":888,"activeCount":98},[],{"intervention":884,"totalTrials":94,"cells":890},{"EARLY_PHASE1":891,"PHASE1":893,"PHASE2":895,"PHASE3":897,"PHASE4":903,"NA":905},{"trials":892,"activeCount":98},[],{"trials":894,"activeCount":98},[],{"trials":896,"activeCount":98},[],{"trials":898,"activeCount":98},[899],{"nctId":875,"briefTitle":876,"status":614,"phases":900,"primaryCompletion":878,"completion":878,"start":879,"enrollment":880,"conditions":901,"interventions":902},[89],[882],[864,884],{"trials":904,"activeCount":98},[],{"trials":906,"activeCount":98},[],{"intervention":908,"totalTrials":94,"cells":909},"misoprostol",{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":914,"PHASE3":916,"PHASE4":929,"NA":931},{"trials":911,"activeCount":98},[],{"trials":913,"activeCount":98},[],{"trials":915,"activeCount":98},[],{"trials":917,"activeCount":98},[918],{"nctId":919,"briefTitle":920,"status":614,"phases":921,"primaryCompletion":922,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":927},"NCT00602095","Labour Induction With Misoprostol, Dinoprostone and Bard Catheter",[89],"2007-03","2004-12",592,[926],"Pregnancy",[908,928],"dinoprostone",{"trials":930,"activeCount":98},[],{"trials":932,"activeCount":98},[],{"intervention":928,"totalTrials":94,"cells":934},{"EARLY_PHASE1":935,"PHASE1":937,"PHASE2":939,"PHASE3":941,"PHASE4":947,"NA":949},{"trials":936,"activeCount":98},[],{"trials":938,"activeCount":98},[],{"trials":940,"activeCount":98},[],{"trials":942,"activeCount":98},[943],{"nctId":919,"briefTitle":920,"status":614,"phases":944,"primaryCompletion":922,"completion":922,"start":923,"enrollment":924,"conditions":945,"interventions":946},[89],[926],[908,928],{"trials":948,"activeCount":98},[],{"trials":950,"activeCount":98},[],{"intervention":952,"totalTrials":94,"cells":953},"Mistletoe extract",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":960,"PHASE4":972,"NA":974},{"trials":955,"activeCount":98},[],{"trials":957,"activeCount":98},[],{"trials":959,"activeCount":98},[],{"trials":961,"activeCount":98},[962],{"nctId":963,"briefTitle":964,"status":614,"phases":965,"primaryCompletion":966,"completion":966,"start":967,"enrollment":968,"conditions":969,"interventions":971},"NCT02948309","Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer",[89],"2022-09","2016-06",290,[970],"Pancreatic Cancer",[952],{"trials":973,"activeCount":98},[],{"trials":975,"activeCount":98},[],{"intervention":977,"totalTrials":94,"cells":978},"Bicalutamide",{"EARLY_PHASE1":979,"PHASE1":981,"PHASE2":983,"PHASE3":985,"PHASE4":997,"NA":999},{"trials":980,"activeCount":98},[],{"trials":982,"activeCount":98},[],{"trials":984,"activeCount":98},[],{"trials":986,"activeCount":98},[987],{"nctId":988,"briefTitle":989,"status":614,"phases":990,"primaryCompletion":991,"completion":992,"start":993,"enrollment":674,"conditions":994,"interventions":996},"NCT02382094","Clinical Trial to Study Quality of Life in Prostate Cancer Patients by Randomizing Anti-androgen Versus Total Androgen Blockage Prior to Curative Intended Radiation Therapy",[89],"2009-04","2012-07","2005-06",[995],"Prostate Cancer",[977],{"trials":998,"activeCount":98},[],{"trials":1000,"activeCount":98},[],{"intervention":1002,"totalTrials":94,"cells":1003},"Femanest",{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1010,"PHASE4":1024,"NA":1026},{"trials":1005,"activeCount":98},[],{"trials":1007,"activeCount":98},[],{"trials":1009,"activeCount":98},[],{"trials":1011,"activeCount":98},[1012],{"nctId":1013,"briefTitle":1014,"status":614,"phases":1015,"completion":1016,"start":1017,"enrollment":1018,"conditions":1019,"interventions":1021},"NCT00564031","Hormonal Replacement Therapy and Small Artery Function",[89],"2004-08","2003-01",66,[1020],"Menopause",[1002,1022,1023],"gestapuran","Femanest plus Gestapuran",{"trials":1025,"activeCount":98},[],{"trials":1027,"activeCount":98},[],{"intervention":1022,"totalTrials":94,"cells":1029},{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1034,"PHASE3":1036,"PHASE4":1042,"NA":1044},{"trials":1031,"activeCount":98},[],{"trials":1033,"activeCount":98},[],{"trials":1035,"activeCount":98},[],{"trials":1037,"activeCount":98},[1038],{"nctId":1013,"briefTitle":1014,"status":614,"phases":1039,"completion":1016,"start":1017,"enrollment":1018,"conditions":1040,"interventions":1041},[89],[1020],[1002,1022,1023],{"trials":1043,"activeCount":98},[],{"trials":1045,"activeCount":98},[],{"intervention":1023,"totalTrials":94,"cells":1047},{"EARLY_PHASE1":1048,"PHASE1":1050,"PHASE2":1052,"PHASE3":1054,"PHASE4":1060,"NA":1062},{"trials":1049,"activeCount":98},[],{"trials":1051,"activeCount":98},[],{"trials":1053,"activeCount":98},[],{"trials":1055,"activeCount":98},[1056],{"nctId":1013,"briefTitle":1014,"status":614,"phases":1057,"completion":1016,"start":1017,"enrollment":1018,"conditions":1058,"interventions":1059},[89],[1020],[1002,1022,1023],{"trials":1061,"activeCount":98},[],{"trials":1063,"activeCount":98},[],{"intervention":1065,"totalTrials":94,"cells":1066},"Prevenar 13",{"EARLY_PHASE1":1067,"PHASE1":1069,"PHASE2":1071,"PHASE3":1073,"PHASE4":1086,"NA":1088},{"trials":1068,"activeCount":98},[],{"trials":1070,"activeCount":98},[],{"trials":1072,"activeCount":98},[],{"trials":1074,"activeCount":98},[1075],{"nctId":1076,"briefTitle":1077,"status":614,"phases":1078,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":1081,"conditions":1082,"interventions":1084},"NCT01892618","Pneumococcal Vaccine in Untreated CLL Patients",[89],"2015-12","2013-08",134,[1083],"Chronic Lymphocytic Leukemia",[1065,1085],"Pneumovax",{"trials":1087,"activeCount":98},[],{"trials":1089,"activeCount":98},[],{"intervention":1085,"totalTrials":94,"cells":1091},{"EARLY_PHASE1":1092,"PHASE1":1094,"PHASE2":1096,"PHASE3":1098,"PHASE4":1104,"NA":1106},{"trials":1093,"activeCount":98},[],{"trials":1095,"activeCount":98},[],{"trials":1097,"activeCount":98},[],{"trials":1099,"activeCount":98},[1100],{"nctId":1076,"briefTitle":1077,"status":614,"phases":1101,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":1081,"conditions":1102,"interventions":1103},[89],[1083],[1065,1085],{"trials":1105,"activeCount":98},[],{"trials":1107,"activeCount":98},[],{"intervention":1109,"totalTrials":94,"cells":1110},"Dexamethasone",{"EARLY_PHASE1":1111,"PHASE1":1113,"PHASE2":1115,"PHASE3":1117,"PHASE4":1131,"NA":1133},{"trials":1112,"activeCount":98},[],{"trials":1114,"activeCount":98},[],{"trials":1116,"activeCount":98},[],{"trials":1118,"activeCount":98},[1119],{"nctId":1120,"briefTitle":1121,"status":614,"phases":1122,"primaryCompletion":1123,"completion":789,"start":1124,"enrollment":1125,"conditions":1126,"interventions":1128},"NCT00426101","Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004",[89],"2011-12","2004-01",368,[1127],"Hemophagocytic Lymphohistiocytosis",[1109,1129,1130],"Etoposide","Cyclosporin",{"trials":1132,"activeCount":98},[],{"trials":1134,"activeCount":98},[],{"intervention":1129,"totalTrials":94,"cells":1136},{"EARLY_PHASE1":1137,"PHASE1":1139,"PHASE2":1141,"PHASE3":1143,"PHASE4":1149,"NA":1151},{"trials":1138,"activeCount":98},[],{"trials":1140,"activeCount":98},[],{"trials":1142,"activeCount":98},[],{"trials":1144,"activeCount":98},[1145],{"nctId":1120,"briefTitle":1121,"status":614,"phases":1146,"primaryCompletion":1123,"completion":789,"start":1124,"enrollment":1125,"conditions":1147,"interventions":1148},[89],[1127],[1109,1129,1130],{"trials":1150,"activeCount":98},[],{"trials":1152,"activeCount":98},[],{"intervention":1130,"totalTrials":94,"cells":1154},{"EARLY_PHASE1":1155,"PHASE1":1157,"PHASE2":1159,"PHASE3":1161,"PHASE4":1167,"NA":1169},{"trials":1156,"activeCount":98},[],{"trials":1158,"activeCount":98},[],{"trials":1160,"activeCount":98},[],{"trials":1162,"activeCount":98},[1163],{"nctId":1120,"briefTitle":1121,"status":614,"phases":1164,"primaryCompletion":1123,"completion":789,"start":1124,"enrollment":1125,"conditions":1165,"interventions":1166},[89],[1127],[1109,1129,1130],{"trials":1168,"activeCount":98},[],{"trials":1170,"activeCount":98},[],{"intervention":1172,"totalTrials":94,"cells":1173},"Acetylsalicylic acid",{"EARLY_PHASE1":1174,"PHASE1":1176,"PHASE2":1178,"PHASE3":1180,"PHASE4":1192,"NA":1194},{"trials":1175,"activeCount":98},[],{"trials":1177,"activeCount":98},[],{"trials":1179,"activeCount":98},[],{"trials":1181,"activeCount":98},[1182],{"nctId":1183,"briefTitle":1184,"status":614,"phases":1185,"primaryCompletion":1186,"completion":1186,"start":1123,"enrollment":1187,"conditions":1188,"interventions":1191},"NCT02482857","Optimal Dose of Acetylsalicylic Acid After Coronary Artery Bypass Grafting",[88,89],"2015-07",45,[1189,1190],"Coronary Artery Bypass Surgery","Stable Angina",[1172],{"trials":1193,"activeCount":98},[],{"trials":1195,"activeCount":98},[],{"intervention":1197,"totalTrials":94,"cells":1198},"Sodium selenite",{"EARLY_PHASE1":1199,"PHASE1":1201,"PHASE2":1203,"PHASE3":1217,"PHASE4":1219,"NA":1221},{"trials":1200,"activeCount":98},[],{"trials":1202,"activeCount":98},[],{"trials":1204,"activeCount":98},[1205],{"nctId":1206,"briefTitle":1207,"status":208,"phases":1208,"primaryCompletion":1209,"completion":1210,"start":170,"enrollment":1211,"conditions":1212,"interventions":1216},"NCT01959438","Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma",[87,88],"2016-10","2018-06",32,[1213,1214,1215],"Malignant Tumor","Treatment Resistant Disorders","Tumor Progression",[1197,1197],{"trials":1218,"activeCount":98},[],{"trials":1220,"activeCount":98},[],{"trials":1222,"activeCount":98},[],{"intervention":1224,"totalTrials":94,"cells":1225},"Chemotherapy",{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1230,"PHASE3":1244,"PHASE4":1246,"NA":1248},{"trials":1227,"activeCount":98},[],{"trials":1229,"activeCount":98},[],{"trials":1231,"activeCount":98},[1232],{"nctId":1233,"briefTitle":1234,"status":614,"phases":1235,"primaryCompletion":1236,"completion":1237,"start":1238,"enrollment":1239,"conditions":1240,"interventions":1243},"NCT01362127","Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia",[88],"2013-06","2018-06-25","2006-10",181,[1241,1242],"Carcinoma, Squamous Cell","Adenocarcinoma of the Esophagus and Gastric Cardia",[1224],{"trials":1245,"activeCount":98},[],{"trials":1247,"activeCount":98},[],{"trials":1249,"activeCount":98},[],{"intervention":1251,"totalTrials":94,"cells":1252},"alemtuzumab",{"EARLY_PHASE1":1253,"PHASE1":1255,"PHASE2":1257,"PHASE3":1267,"PHASE4":1269,"NA":1271},{"trials":1254,"activeCount":98},[],{"trials":1256,"activeCount":98},[],{"trials":1258,"activeCount":98},[1259],{"nctId":1260,"briefTitle":1261,"status":614,"phases":1262,"completion":623,"start":1263,"enrollment":212,"conditions":1264,"interventions":1266},"NCT00162851","Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia",[88],"2003-04",[1265],"B-CLL",[1251],{"trials":1268,"activeCount":98},[],{"trials":1270,"activeCount":98},[],{"trials":1272,"activeCount":98},[],{"intervention":1274,"totalTrials":94,"cells":1275},"MSC-KI-PL-204",{"EARLY_PHASE1":1276,"PHASE1":1278,"PHASE2":1280,"PHASE3":1295,"PHASE4":1297,"NA":1299},{"trials":1277,"activeCount":98},[],{"trials":1279,"activeCount":98},[],{"trials":1281,"activeCount":98},[1282],{"nctId":1283,"briefTitle":1284,"status":614,"phases":1285,"primaryCompletion":1286,"completion":1286,"start":1287,"enrollment":1288,"conditions":1289,"interventions":1294},"NCT04290182","A Study of Local Administration of Autologous Mesenchymal Stromal Cells in Dysphonic Patients With Vocal Fold Scarring",[87,88],"2025-01-01","2021-03-01",9,[1290,1291,1292,1293],"Hoarseness","Dysphonia","Aphonia","Vocal Fold Scar",[1274],{"trials":1296,"activeCount":98},[],{"trials":1298,"activeCount":98},[],{"trials":1300,"activeCount":98},[],{"intervention":263,"totalTrials":94,"cells":1302},{"EARLY_PHASE1":1303,"PHASE1":1305,"PHASE2":1307,"PHASE3":1313,"PHASE4":1315,"NA":1317},{"trials":1304,"activeCount":98},[],{"trials":1306,"activeCount":98},[],{"trials":1308,"activeCount":98},[1309],{"nctId":252,"briefTitle":253,"status":208,"phases":1310,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":1311,"interventions":1312},[87,88],[260,261],[229,263],{"trials":1314,"activeCount":98},[],{"trials":1316,"activeCount":98},[],{"trials":1318,"activeCount":98},[],{"intervention":1320,"totalTrials":94,"cells":1321},"Hyperbaric oxygen",{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1326,"PHASE3":1343,"PHASE4":1345,"NA":1347},{"trials":1323,"activeCount":98},[],{"trials":1325,"activeCount":98},[],{"trials":1327,"activeCount":98},[1328],{"nctId":1329,"briefTitle":1330,"status":614,"phases":1331,"primaryCompletion":593,"completion":1332,"start":1333,"enrollment":1334,"conditions":1335,"interventions":1342},"NCT04842448","Safety and Efficacy of Hyperbaric Oxygen Therapy for Long COVID Syndrome",[88],"2024-06-17","2021-09-15",80,[1336,1337,1338,1339,1340,1341],"COVID-19","Post COVID-19 Condition","Post COVID-19 Condition, Unspecified","Post COVID Condition","Post-COVID Syndrome","Post-Acute COVID-19 Syndrome",[1320],{"trials":1344,"activeCount":98},[],{"trials":1346,"activeCount":98},[],{"trials":1348,"activeCount":98},[],{"intervention":1350,"totalTrials":94,"cells":1351},"Omegaven®",{"EARLY_PHASE1":1352,"PHASE1":1354,"PHASE2":1356,"PHASE3":1369,"PHASE4":1371,"NA":1373},{"trials":1353,"activeCount":98},[],{"trials":1355,"activeCount":98},[],{"trials":1357,"activeCount":98},[1358],{"nctId":1359,"briefTitle":1360,"status":614,"phases":1361,"primaryCompletion":1362,"completion":1363,"start":1364,"enrollment":1365,"conditions":1366,"interventions":1367},"NCT04647604","Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -",[88],"2021-01-05","2021-07-07","2020-06-23",23,[1336],[1350,1368],"Sodium chloride",{"trials":1370,"activeCount":98},[],{"trials":1372,"activeCount":98},[],{"trials":1374,"activeCount":98},[],{"intervention":1368,"totalTrials":94,"cells":1376},{"EARLY_PHASE1":1377,"PHASE1":1379,"PHASE2":1381,"PHASE3":1387,"PHASE4":1389,"NA":1391},{"trials":1378,"activeCount":98},[],{"trials":1380,"activeCount":98},[],{"trials":1382,"activeCount":98},[1383],{"nctId":1359,"briefTitle":1360,"status":614,"phases":1384,"primaryCompletion":1362,"completion":1363,"start":1364,"enrollment":1365,"conditions":1385,"interventions":1386},[88],[1336],[1350,1368],{"trials":1388,"activeCount":98},[],{"trials":1390,"activeCount":98},[],{"trials":1392,"activeCount":98},[],{"intervention":1394,"totalTrials":94,"cells":1395},"Pemirolast",{"EARLY_PHASE1":1396,"PHASE1":1398,"PHASE2":1400,"PHASE3":1410,"PHASE4":1412,"NA":1414},{"trials":1397,"activeCount":98},[],{"trials":1399,"activeCount":98},[],{"trials":1401,"activeCount":98},[1402],{"nctId":1403,"briefTitle":1404,"status":294,"phases":1405,"primaryCompletion":1406,"completion":1406,"start":790,"enrollment":94,"conditions":1407,"interventions":1409},"NCT03119714","Pemirolast in Allergen Challenge (PEMAG)",[88],"2018-02",[1408],"Allergic Asthma",[1394],{"trials":1411,"activeCount":98},[],{"trials":1413,"activeCount":98},[],{"trials":1415,"activeCount":98},[],{"intervention":1417,"totalTrials":94,"cells":1418},"Cetuximab",{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1423,"PHASE3":1435,"PHASE4":1437,"NA":1439},{"trials":1420,"activeCount":98},[],{"trials":1422,"activeCount":98},[],{"trials":1424,"activeCount":98},[1425],{"nctId":1426,"briefTitle":1427,"status":208,"phases":1428,"primaryCompletion":1429,"completion":1430,"start":878,"enrollment":1431,"conditions":1432,"interventions":1434},"NCT01830556","Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck",[88],"2013-11","2015-11",120,[1433],"Squamous Cell Carcinoma of the Head and Neck",[1417],{"trials":1436,"activeCount":98},[],{"trials":1438,"activeCount":98},[],{"trials":1440,"activeCount":98},[],{"intervention":1442,"totalTrials":94,"cells":1443},"Vigantol",{"EARLY_PHASE1":1444,"PHASE1":1446,"PHASE2":1448,"PHASE3":1460,"PHASE4":1462,"NA":1464},{"trials":1445,"activeCount":98},[],{"trials":1447,"activeCount":98},[],{"trials":1449,"activeCount":98},[1450],{"nctId":1451,"briefTitle":1452,"status":614,"phases":1453,"primaryCompletion":1454,"completion":1454,"start":1455,"enrollment":1456,"conditions":1457,"interventions":1459},"NCT01131858","Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency",[87,88],"2011-06","2010-03",140,[1458],"Primary Immune Deficiency Disorder",[1442],{"trials":1461,"activeCount":98},[],{"trials":1463,"activeCount":98},[],{"trials":1465,"activeCount":98},[],{"intervention":1467,"totalTrials":94,"cells":1468},"desferal",{"EARLY_PHASE1":1469,"PHASE1":1471,"PHASE2":1473,"PHASE3":1487,"PHASE4":1489,"NA":1491},{"trials":1470,"activeCount":98},[],{"trials":1472,"activeCount":98},[],{"trials":1474,"activeCount":98},[1475],{"nctId":1476,"briefTitle":1477,"status":208,"phases":1478,"primaryCompletion":1479,"completion":1480,"start":1481,"enrollment":1482,"conditions":1483,"interventions":1485},"NCT03085771","Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes",[88],"2023-12-12","2024-12-12","2017-01-01",30,[1484],"Diabetes Mellitus, Type 1",[1467,1486],"Isotonic saline",{"trials":1488,"activeCount":98},[],{"trials":1490,"activeCount":98},[],{"trials":1492,"activeCount":98},[],{"intervention":1486,"totalTrials":94,"cells":1494},{"EARLY_PHASE1":1495,"PHASE1":1497,"PHASE2":1499,"PHASE3":1505,"PHASE4":1507,"NA":1509},{"trials":1496,"activeCount":98},[],{"trials":1498,"activeCount":98},[],{"trials":1500,"activeCount":98},[1501],{"nctId":1476,"briefTitle":1477,"status":208,"phases":1502,"primaryCompletion":1479,"completion":1480,"start":1481,"enrollment":1482,"conditions":1503,"interventions":1504},[88],[1484],[1467,1486],{"trials":1506,"activeCount":98},[],{"trials":1508,"activeCount":98},[],{"trials":1510,"activeCount":98},[],{"intervention":1512,"totalTrials":94,"cells":1513},"Anakinra Prefilled Syringe",{"EARLY_PHASE1":1514,"PHASE1":1516,"PHASE2":1518,"PHASE3":1532,"PHASE4":1534,"NA":1536},{"trials":1515,"activeCount":98},[],{"trials":1517,"activeCount":98},[],{"trials":1519,"activeCount":98},[1520],{"nctId":1521,"briefTitle":1522,"status":208,"phases":1523,"primaryCompletion":1524,"completion":1525,"start":1526,"enrollment":1431,"conditions":1527,"interventions":1529},"NCT04412291","A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study",[88],"2021-03","2021-06","2020-06-11",[1528],"Covid-19",[1512,1530,1531],"Tocilizumab Prefilled Syringe","Standard-of-care treatment",{"trials":1533,"activeCount":98},[],{"trials":1535,"activeCount":98},[],{"trials":1537,"activeCount":98},[],{"intervention":1530,"totalTrials":94,"cells":1539},{"EARLY_PHASE1":1540,"PHASE1":1542,"PHASE2":1544,"PHASE3":1550,"PHASE4":1552,"NA":1554},{"trials":1541,"activeCount":98},[],{"trials":1543,"activeCount":98},[],{"trials":1545,"activeCount":98},[1546],{"nctId":1521,"briefTitle":1522,"status":208,"phases":1547,"primaryCompletion":1524,"completion":1525,"start":1526,"enrollment":1431,"conditions":1548,"interventions":1549},[88],[1528],[1512,1530,1531],{"trials":1551,"activeCount":98},[],{"trials":1553,"activeCount":98},[],{"trials":1555,"activeCount":98},[],{"intervention":1531,"totalTrials":94,"cells":1557},{"EARLY_PHASE1":1558,"PHASE1":1560,"PHASE2":1562,"PHASE3":1568,"PHASE4":1570,"NA":1572},{"trials":1559,"activeCount":98},[],{"trials":1561,"activeCount":98},[],{"trials":1563,"activeCount":98},[1564],{"nctId":1521,"briefTitle":1522,"status":208,"phases":1565,"primaryCompletion":1524,"completion":1525,"start":1526,"enrollment":1431,"conditions":1566,"interventions":1567},[88],[1528],[1512,1530,1531],{"trials":1569,"activeCount":98},[],{"trials":1571,"activeCount":98},[],{"trials":1573,"activeCount":98},[],{"intervention":1575,"totalTrials":94,"cells":1576},"Tamoxifen 20 mg",{"EARLY_PHASE1":1577,"PHASE1":1579,"PHASE2":1581,"PHASE3":1597,"PHASE4":1599,"NA":1601},{"trials":1578,"activeCount":98},[],{"trials":1580,"activeCount":98},[],{"trials":1582,"activeCount":98},[1583],{"nctId":1584,"briefTitle":1585,"status":208,"phases":1586,"primaryCompletion":1587,"completion":1588,"start":1589,"enrollment":1590,"conditions":1591,"interventions":1596},"NCT05133674","Therapeutic Dose Monitoring (TDM) of Tamoxifen",[88],"2022-12-31","2023-03-01","2022-04-04",40,[18,1592,1593,1594,1595],"Breast Carcinoma","Breast Tumors","Cancer of Breast","Malignant Neoplasm of Breast",[1575],{"trials":1598,"activeCount":98},[],{"trials":1600,"activeCount":98},[],{"trials":1602,"activeCount":98},[],{"intervention":1604,"totalTrials":94,"cells":1605},"Prevenar13",{"EARLY_PHASE1":1606,"PHASE1":1608,"PHASE2":1610,"PHASE3":1621,"PHASE4":1623,"NA":1625},{"trials":1607,"activeCount":98},[],{"trials":1609,"activeCount":98},[],{"trials":1611,"activeCount":98},[1612],{"nctId":1613,"briefTitle":1614,"status":614,"phases":1615,"primaryCompletion":1429,"completion":1616,"start":1617,"enrollment":212,"conditions":1618,"interventions":1620},"NCT01847781","PNEUMOCELL - Conjugated Pneumococcal Vaccination in Patients With Immunoglobulin G-deficiency",[88],"2013-12","2013-05",[1619],"IgG Deficiency",[1604],{"trials":1622,"activeCount":98},[],{"trials":1624,"activeCount":98},[],{"trials":1626,"activeCount":98},[],{"intervention":1628,"totalTrials":94,"cells":1629},"Revlimid",{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1634,"PHASE3":1646,"PHASE4":1648,"NA":1650},{"trials":1631,"activeCount":98},[],{"trials":1633,"activeCount":98},[],{"trials":1635,"activeCount":98},[1636],{"nctId":1637,"briefTitle":1638,"status":614,"phases":1639,"primaryCompletion":1640,"start":1641,"enrollment":1642,"conditions":1643,"interventions":1645},"NCT01450215","Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma",[88],"2016-01","2011-03",62,[1644],"Multiple Myeloma",[1628],{"trials":1647,"activeCount":98},[],{"trials":1649,"activeCount":98},[],{"trials":1651,"activeCount":98},[],{"intervention":303,"totalTrials":94,"cells":1653},{"EARLY_PHASE1":1654,"PHASE1":1656,"PHASE2":1658,"PHASE3":1664,"PHASE4":1666,"NA":1668},{"trials":1655,"activeCount":98},[],{"trials":1657,"activeCount":98},[],{"trials":1659,"activeCount":98},[1660],{"nctId":292,"briefTitle":293,"status":294,"phases":1661,"primaryCompletion":296,"completion":297,"start":298,"enrollment":299,"conditions":1662,"interventions":1663},[88],[301],[59,303],{"trials":1665,"activeCount":98},[],{"trials":1667,"activeCount":98},[],{"trials":1669,"activeCount":98},[],{"intervention":1671,"totalTrials":94,"cells":1672},"Testosterone cream 1%",{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1691,"PHASE4":1693,"NA":1695},{"trials":1674,"activeCount":98},[],{"trials":1676,"activeCount":98},[],{"trials":1678,"activeCount":98},[1679],{"nctId":1680,"briefTitle":1681,"status":614,"phases":1682,"primaryCompletion":1683,"completion":1683,"start":1684,"enrollment":1685,"conditions":1686,"interventions":1690},"NCT03210558","Study of Testosterone and Athlete Response",[88],"2018-06-20","2017-05-26",48,[1687,1688,1689],"Athletic Performance","Testosterone","Women's Health: Female Athlete\u002FFemale Athlete Triad",[1671],{"trials":1692,"activeCount":98},[],{"trials":1694,"activeCount":98},[],{"trials":1696,"activeCount":98},[],{"intervention":1698,"totalTrials":94,"cells":1699},"autologous NK cells",{"EARLY_PHASE1":1700,"PHASE1":1702,"PHASE2":1713,"PHASE3":1715,"PHASE4":1717,"NA":1719},{"trials":1701,"activeCount":98},[],{"trials":1703,"activeCount":98},[1704],{"nctId":1705,"briefTitle":1706,"status":208,"phases":1707,"primaryCompletion":1708,"completion":1587,"start":1709,"enrollment":1710,"conditions":1711,"interventions":1712},"NCT04558853","Clinical Study of Autologous Natural Killer Cells in Multiple Myeloma",[87],"2021-12-31","2014-01-01",12,[1644],[1698],{"trials":1714,"activeCount":98},[],{"trials":1716,"activeCount":98},[],{"trials":1718,"activeCount":98},[],{"trials":1720,"activeCount":98},[],{"intervention":216,"totalTrials":94,"cells":1722},{"EARLY_PHASE1":1723,"PHASE1":1725,"PHASE2":1731,"PHASE3":1733,"PHASE4":1735,"NA":1737},{"trials":1724,"activeCount":98},[],{"trials":1726,"activeCount":98},[1727],{"nctId":206,"briefTitle":207,"status":208,"phases":1728,"primaryCompletion":210,"completion":210,"start":211,"enrollment":212,"conditions":1729,"interventions":1730},[87],[214],[198,216,217,218,219],{"trials":1732,"activeCount":98},[],{"trials":1734,"activeCount":98},[],{"trials":1736,"activeCount":98},[],{"trials":1738,"activeCount":98},[],{"intervention":217,"totalTrials":94,"cells":1740},{"EARLY_PHASE1":1741,"PHASE1":1743,"PHASE2":1749,"PHASE3":1751,"PHASE4":1753,"NA":1755},{"trials":1742,"activeCount":98},[],{"trials":1744,"activeCount":98},[1745],{"nctId":206,"briefTitle":207,"status":208,"phases":1746,"primaryCompletion":210,"completion":210,"start":211,"enrollment":212,"conditions":1747,"interventions":1748},[87],[214],[198,216,217,218,219],{"trials":1750,"activeCount":98},[],{"trials":1752,"activeCount":98},[],{"trials":1754,"activeCount":98},[],{"trials":1756,"activeCount":98},[],{"intervention":218,"totalTrials":94,"cells":1758},{"EARLY_PHASE1":1759,"PHASE1":1761,"PHASE2":1767,"PHASE3":1769,"PHASE4":1771,"NA":1773},{"trials":1760,"activeCount":98},[],{"trials":1762,"activeCount":98},[1763],{"nctId":206,"briefTitle":207,"status":208,"phases":1764,"primaryCompletion":210,"completion":210,"start":211,"enrollment":212,"conditions":1765,"interventions":1766},[87],[214],[198,216,217,218,219],{"trials":1768,"activeCount":98},[],{"trials":1770,"activeCount":98},[],{"trials":1772,"activeCount":98},[],{"trials":1774,"activeCount":98},[],{"intervention":219,"totalTrials":94,"cells":1776},{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1785,"PHASE3":1787,"PHASE4":1789,"NA":1791},{"trials":1778,"activeCount":98},[],{"trials":1780,"activeCount":98},[1781],{"nctId":206,"briefTitle":207,"status":208,"phases":1782,"primaryCompletion":210,"completion":210,"start":211,"enrollment":212,"conditions":1783,"interventions":1784},[87],[214],[198,216,217,218,219],{"trials":1786,"activeCount":98},[],{"trials":1788,"activeCount":98},[],{"trials":1790,"activeCount":98},[],{"trials":1792,"activeCount":98},[],{"intervention":1794,"totalTrials":94,"cells":1795},"aMSC",{"EARLY_PHASE1":1796,"PHASE1":1798,"PHASE2":1813,"PHASE3":1815,"PHASE4":1817,"NA":1819},{"trials":1797,"activeCount":98},[],{"trials":1799,"activeCount":98},[1800],{"nctId":1801,"briefTitle":1802,"status":614,"phases":1803,"primaryCompletion":1804,"completion":1804,"start":1805,"enrollment":1806,"conditions":1807,"interventions":1811},"NCT01981330","Pilot Study of Stem Cell Treatment of Patients With Vocal Fold Scarring",[87],"2020-02-24","2012-01",16,[1808,1809,1810],"Improved Healing of Scarred Vocal Folds","Improved Vocal Fold Status","Improved Vocal Fold Function",[1794,1812],"aMSC+hyaluronan gel",{"trials":1814,"activeCount":98},[],{"trials":1816,"activeCount":98},[],{"trials":1818,"activeCount":98},[],{"trials":1820,"activeCount":98},[],{"intervention":1812,"totalTrials":94,"cells":1822},{"EARLY_PHASE1":1823,"PHASE1":1825,"PHASE2":1831,"PHASE3":1833,"PHASE4":1835,"NA":1837},{"trials":1824,"activeCount":98},[],{"trials":1826,"activeCount":98},[1827],{"nctId":1801,"briefTitle":1802,"status":614,"phases":1828,"primaryCompletion":1804,"completion":1804,"start":1805,"enrollment":1806,"conditions":1829,"interventions":1830},[87],[1808,1809,1810],[1794,1812],{"trials":1832,"activeCount":98},[],{"trials":1834,"activeCount":98},[],{"trials":1836,"activeCount":98},[],{"trials":1838,"activeCount":98},[],{"intervention":1840,"totalTrials":94,"cells":1841},"aprepitant",{"EARLY_PHASE1":1842,"PHASE1":1844,"PHASE2":1859,"PHASE3":1861,"PHASE4":1863,"NA":1865},{"trials":1843,"activeCount":98},[],{"trials":1845,"activeCount":98},[1846],{"nctId":1847,"briefTitle":1848,"status":208,"phases":1849,"primaryCompletion":1850,"completion":1851,"start":1852,"enrollment":1853,"conditions":1854,"interventions":1857},"NCT00726960","Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers",[87],"2009-12","2010-06","2008-01",60,[1855,699,1856],"Opioid-Related Disorders","Substance-Related Disorders",[1840,1858],"Pseudo-placebo - buprenorphine",{"trials":1860,"activeCount":98},[],{"trials":1862,"activeCount":98},[],{"trials":1864,"activeCount":98},[],{"trials":1866,"activeCount":98},[],{"intervention":1858,"totalTrials":94,"cells":1868},{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1877,"PHASE3":1879,"PHASE4":1881,"NA":1883},{"trials":1870,"activeCount":98},[],{"trials":1872,"activeCount":98},[1873],{"nctId":1847,"briefTitle":1848,"status":208,"phases":1874,"primaryCompletion":1850,"completion":1851,"start":1852,"enrollment":1853,"conditions":1875,"interventions":1876},[87],[1855,699,1856],[1840,1858],{"trials":1878,"activeCount":98},[],{"trials":1880,"activeCount":98},[],{"trials":1882,"activeCount":98},[],{"trials":1884,"activeCount":98},[],{"intervention":1886,"totalTrials":94,"cells":1887},"68Ga-NOTA-PEG2-RM26",{"EARLY_PHASE1":1888,"PHASE1":1890,"PHASE2":1901,"PHASE3":1903,"PHASE4":1905,"NA":1907},{"trials":1889,"activeCount":98},[],{"trials":1891,"activeCount":98},[1892],{"nctId":1893,"briefTitle":1894,"status":208,"phases":1895,"primaryCompletion":1896,"completion":1896,"start":1897,"enrollment":625,"conditions":1898,"interventions":1900},"NCT06147362","68Ga-NOTA-PEG2-RM26 PET\u002FCT, First in Man Study",[87],"2023-12-31","2022-06-01",[1899],"Cancer",[1886],{"trials":1902,"activeCount":98},[],{"trials":1904,"activeCount":98},[],{"trials":1906,"activeCount":98},[],{"trials":1908,"activeCount":98},[],{"intervention":1910,"totalTrials":94,"cells":1911},"Mesenchymal stromal cells",{"EARLY_PHASE1":1912,"PHASE1":1914,"PHASE2":1925,"PHASE3":1927,"PHASE4":1929,"NA":1931},{"trials":1913,"activeCount":98},[],{"trials":1915,"activeCount":98},[1916],{"nctId":1917,"briefTitle":1918,"status":208,"phases":1919,"primaryCompletion":1079,"start":1920,"enrollment":1921,"conditions":1922,"interventions":1924},"NCT02215811","Treatment of Severe Acute Respiratory Distress Syndrome With Allogeneic Bone Marrow-derived Mesenchymal Stromal Cells",[87],"2014-03",10,[1923],"Acute Respiratory Distress Syndrome, Adult",[1910],{"trials":1926,"activeCount":98},[],{"trials":1928,"activeCount":98},[],{"trials":1930,"activeCount":98},[],{"trials":1932,"activeCount":98},[],{"intervention":1934,"totalTrials":94,"cells":1935},"Temporary Stopping",{"EARLY_PHASE1":1936,"PHASE1":1938,"PHASE2":1950,"PHASE3":1952,"PHASE4":1954,"NA":1956},{"trials":1937,"activeCount":98},[],{"trials":1939,"activeCount":98},[1940],{"nctId":1941,"briefTitle":1942,"status":208,"phases":1943,"primaryCompletion":1944,"completion":1945,"start":1946,"enrollment":212,"conditions":1947,"interventions":1949},"NCT06127940","K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation",[87],"2025-06-01","2026-01-01","2023-10-15",[1948],"Non-small Cell Lung Cancer Metastatic",[1934],{"trials":1951,"activeCount":98},[],{"trials":1953,"activeCount":98},[],{"trials":1955,"activeCount":98},[],{"trials":1957,"activeCount":98},[],{"intervention":1959,"totalTrials":94,"cells":1960},"rituximab",{"EARLY_PHASE1":1961,"PHASE1":1963,"PHASE2":1974,"PHASE3":1976,"PHASE4":1978,"NA":1980},{"trials":1962,"activeCount":98},[],{"trials":1964,"activeCount":98},[1965],{"nctId":1966,"briefTitle":1967,"status":614,"phases":1968,"completion":1969,"start":1970,"enrollment":1456,"conditions":1971,"interventions":1973},"NCT00255593","Safety and Efficacy Study of Rituximab in Renal Transplantation",[87],"2007-10","2005-11",[1972],"Renal Transplantation",[1959],{"trials":1975,"activeCount":98},[],{"trials":1977,"activeCount":98},[],{"trials":1979,"activeCount":98},[],{"trials":1981,"activeCount":98},[],{"intervention":1983,"totalTrials":94,"cells":1984},"Vaccination with vaccine against hepatitis A and B",{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":1989,"PHASE3":1991,"PHASE4":1993,"NA":1995},{"trials":1986,"activeCount":98},[],{"trials":1988,"activeCount":98},[],{"trials":1990,"activeCount":98},[],{"trials":1992,"activeCount":98},[],{"trials":1994,"activeCount":98},[],{"trials":1996,"activeCount":98},[1997],{"nctId":1998,"briefTitle":1999,"status":2000,"phases":2001,"primaryCompletion":2002,"completion":53,"start":2003,"enrollment":98,"conditions":2004,"interventions":2008},"NCT02605538","Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively","WITHDRAWN",[91],"2023-12","2015-09-01",[23,2005,2006,2007],"Hepatitis A","Hepatitis B","Tuberculosis",[1983],{"intervention":2010,"totalTrials":94,"cells":2011},"IV amino acids",{"EARLY_PHASE1":2012,"PHASE1":2014,"PHASE2":2016,"PHASE3":2018,"PHASE4":2020,"NA":2022},{"trials":2013,"activeCount":98},[],{"trials":2015,"activeCount":98},[],{"trials":2017,"activeCount":98},[],{"trials":2019,"activeCount":98},[],{"trials":2021,"activeCount":98},[],{"trials":2023,"activeCount":98},[2024],{"nctId":2025,"briefTitle":2026,"status":671,"phases":2027,"primaryCompletion":2028,"completion":2028,"start":2029,"enrollment":2030,"conditions":2031,"interventions":2033},"NCT05197231","Investigating the Anabolic Response to Resistance Exercise During Critical Illness",[91],"2027-12","2022-12-25",24,[15,2032],"Muscle Loss",[2010],{"intervention":2035,"totalTrials":94,"cells":2036},"Resuscitation fluid",{"EARLY_PHASE1":2037,"PHASE1":2039,"PHASE2":2041,"PHASE3":2043,"PHASE4":2045,"NA":2047},{"trials":2038,"activeCount":98},[],{"trials":2040,"activeCount":98},[],{"trials":2042,"activeCount":98},[],{"trials":2044,"activeCount":98},[],{"trials":2046,"activeCount":98},[],{"trials":2048,"activeCount":98},[2049],{"nctId":2050,"briefTitle":2051,"status":614,"phases":2052,"primaryCompletion":2053,"completion":2054,"start":2055,"enrollment":2056,"conditions":2057,"interventions":2059},"NCT05629780","Temporal Changes of Lactate in CLASSIC Patients",[91],"2022-12-28","2023-06-14","2022-09-29",777,[2058],"Septic Shock",[2035],{"intervention":2061,"totalTrials":94,"cells":2062},"Immunosuppressive Agents",{"EARLY_PHASE1":2063,"PHASE1":2065,"PHASE2":2067,"PHASE3":2069,"PHASE4":2071,"NA":2073},{"trials":2064,"activeCount":98},[],{"trials":2066,"activeCount":98},[],{"trials":2068,"activeCount":98},[],{"trials":2070,"activeCount":98},[],{"trials":2072,"activeCount":98},[],{"trials":2074,"activeCount":98},[2075],{"nctId":2076,"briefTitle":2077,"status":614,"phases":2078,"primaryCompletion":2079,"start":2080,"enrollment":2081,"conditions":2082,"interventions":2085},"NCT01813617","Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis",[],"2012-06","2010-09",72,[2083,2084],"Polymyositis","Dermatomyositis",[2061],{"intervention":2087,"totalTrials":94,"cells":2088},"Piperacillin\u002Ftazobactam, Meropenem",{"EARLY_PHASE1":2089,"PHASE1":2091,"PHASE2":2093,"PHASE3":2095,"PHASE4":2097,"NA":2099},{"trials":2090,"activeCount":98},[],{"trials":2092,"activeCount":98},[],{"trials":2094,"activeCount":98},[],{"trials":2096,"activeCount":98},[],{"trials":2098,"activeCount":98},[],{"trials":2100,"activeCount":98},[2101],{"nctId":2102,"briefTitle":2103,"status":208,"phases":2104,"primaryCompletion":1587,"completion":1896,"start":2105,"enrollment":625,"conditions":2106,"interventions":2108},"NCT05134298","Pharmacokinetics of Piperacillin and Meropenem in ICU Patients",[],"2019-11-01",[2107],"Antibiotic Pharmacokinetics",[2087],{"intervention":2110,"totalTrials":94,"cells":2111},"NGS",{"EARLY_PHASE1":2112,"PHASE1":2114,"PHASE2":2116,"PHASE3":2118,"PHASE4":2120,"NA":2122},{"trials":2113,"activeCount":98},[],{"trials":2115,"activeCount":98},[],{"trials":2117,"activeCount":98},[],{"trials":2119,"activeCount":98},[],{"trials":2121,"activeCount":98},[],{"trials":2123,"activeCount":98},[2124],{"nctId":2125,"briefTitle":2126,"status":614,"phases":2127,"primaryCompletion":2128,"completion":2129,"start":38,"enrollment":2130,"conditions":2131,"interventions":2133},"NCT02767700","NGS and TME for Evidence-based Treatment of Pancreatic Cancer",[],"2018-03-25","2018-08-31",39,[2132],"Pancreatic Ductal Adenocarcinoma",[2110],{"intervention":2135,"totalTrials":94,"cells":2136},"Rifampicin treatment",{"EARLY_PHASE1":2137,"PHASE1":2139,"PHASE2":2141,"PHASE3":2143,"PHASE4":2145,"NA":2147},{"trials":2138,"activeCount":98},[],{"trials":2140,"activeCount":98},[],{"trials":2142,"activeCount":98},[],{"trials":2144,"activeCount":98},[],{"trials":2146,"activeCount":98},[],{"trials":2148,"activeCount":98},[2149],{"nctId":2150,"briefTitle":2151,"status":614,"phases":2152,"primaryCompletion":2153,"completion":2153,"start":2154,"enrollment":2030,"conditions":2155,"interventions":2157},"NCT01340456","Cholesterol Metabolites as Markers for CYP3A Induction",[91],"2011-07","2011-05",[2156],"CYP3A4 Induction",[2135],{"intervention":2159,"totalTrials":94,"cells":2160},"cholecalciferol and calcium carbonate",{"EARLY_PHASE1":2161,"PHASE1":2163,"PHASE2":2165,"PHASE3":2167,"PHASE4":2169,"NA":2171},{"trials":2162,"activeCount":98},[],{"trials":2164,"activeCount":98},[],{"trials":2166,"activeCount":98},[],{"trials":2168,"activeCount":98},[],{"trials":2170,"activeCount":98},[],{"trials":2172,"activeCount":98},[2173],{"nctId":2174,"briefTitle":2175,"status":614,"phases":2176,"primaryCompletion":2177,"completion":2177,"start":2178,"enrollment":2179,"conditions":2180,"interventions":2182},"NCT00982722","Vitamin D Supplementation After Parathyroid Surgery",[91],"2018-05-04","2008-04",150,[2181],"Primary Hyperparathyroidism",[2159,2183],"calcium carbonate",{"intervention":2183,"totalTrials":94,"cells":2185},{"EARLY_PHASE1":2186,"PHASE1":2188,"PHASE2":2190,"PHASE3":2192,"PHASE4":2194,"NA":2196},{"trials":2187,"activeCount":98},[],{"trials":2189,"activeCount":98},[],{"trials":2191,"activeCount":98},[],{"trials":2193,"activeCount":98},[],{"trials":2195,"activeCount":98},[],{"trials":2197,"activeCount":98},[2198],{"nctId":2174,"briefTitle":2175,"status":614,"phases":2199,"primaryCompletion":2177,"completion":2177,"start":2178,"enrollment":2179,"conditions":2200,"interventions":2201},[91],[2181],[2159,2183],{"intervention":2203,"totalTrials":94,"cells":2204},"Oral contraceptive",{"EARLY_PHASE1":2205,"PHASE1":2207,"PHASE2":2209,"PHASE3":2211,"PHASE4":2213,"NA":2215},{"trials":2206,"activeCount":98},[],{"trials":2208,"activeCount":98},[],{"trials":2210,"activeCount":98},[],{"trials":2212,"activeCount":98},[],{"trials":2214,"activeCount":98},[],{"trials":2216,"activeCount":98},[2217],{"nctId":2218,"briefTitle":2219,"status":208,"phases":2220,"primaryCompletion":2221,"completion":1079,"start":2222,"enrollment":594,"conditions":2223,"interventions":2225},"NCT02257671","Oral Contraceptives and Economic Behaviour",[91],"2015-08","2012-02",[2224],"Female Contraception",[2203],{"intervention":2227,"totalTrials":94,"cells":2228},"Norditropin SimpleXx",{"EARLY_PHASE1":2229,"PHASE1":2231,"PHASE2":2233,"PHASE3":2235,"PHASE4":2237,"NA":2239},{"trials":2230,"activeCount":98},[],{"trials":2232,"activeCount":98},[],{"trials":2234,"activeCount":98},[],{"trials":2236,"activeCount":98},[],{"trials":2238,"activeCount":98},[],{"trials":2240,"activeCount":98},[2241],{"nctId":2242,"briefTitle":2243,"status":614,"phases":2244,"primaryCompletion":1455,"completion":1455,"start":2245,"enrollment":2246,"conditions":2247,"interventions":2249},"NCT00372125","Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome",[91],"2005-04",46,[2248],"Prader-Willi Syndrome",[2227],{"intervention":2251,"totalTrials":94,"cells":2252},"EPAX 1050TG",{"EARLY_PHASE1":2253,"PHASE1":2255,"PHASE2":2257,"PHASE3":2259,"PHASE4":2261,"NA":2263},{"trials":2254,"activeCount":98},[],{"trials":2256,"activeCount":98},[],{"trials":2258,"activeCount":98},[],{"trials":2260,"activeCount":98},[],{"trials":2262,"activeCount":98},[],{"trials":2264,"activeCount":98},[2265],{"nctId":2266,"briefTitle":2267,"status":614,"phases":2268,"start":2269,"enrollment":12,"conditions":2270,"interventions":2272},"NCT00211159","OmegAD (Omega-3 and Alzheimer's Disease)",[91],"2000-12",[2271],"Alzheimer's Disease",[2251],{"intervention":795,"totalTrials":94,"cells":2274},{"EARLY_PHASE1":2275,"PHASE1":2277,"PHASE2":2279,"PHASE3":2281,"PHASE4":2283,"NA":2285},{"trials":2276,"activeCount":98},[],{"trials":2278,"activeCount":98},[],{"trials":2280,"activeCount":98},[],{"trials":2282,"activeCount":98},[],{"trials":2284,"activeCount":98},[],{"trials":2286,"activeCount":98},[2287],{"nctId":2288,"briefTitle":2289,"status":614,"phases":2290,"primaryCompletion":2291,"completion":1640,"start":2292,"enrollment":2293,"conditions":2294,"interventions":2296},"NCT02292277","Ticagrelor Pharmacokinetics in NSTEMI",[],"2015-10","2014-10",63,[2295],"Myocardial Infarction",[795],{"intervention":2298,"totalTrials":94,"cells":2299},"Montelukast",{"EARLY_PHASE1":2300,"PHASE1":2302,"PHASE2":2304,"PHASE3":2306,"PHASE4":2308,"NA":2310},{"trials":2301,"activeCount":98},[],{"trials":2303,"activeCount":98},[],{"trials":2305,"activeCount":98},[],{"trials":2307,"activeCount":98},[],{"trials":2309,"activeCount":98},[],{"trials":2311,"activeCount":98},[2312],{"nctId":2313,"briefTitle":2314,"status":208,"phases":2315,"primaryCompletion":2316,"completion":2317,"start":2318,"enrollment":880,"conditions":2319,"interventions":2321},"NCT01841164","A Mechanistic Study to Evaluate the Efficacy of Montelukast on Airway Function in Asthma",[91],"2014-06","2014-12","2012-05",[2320],"Asthma",[2298],{"intervention":2323,"totalTrials":94,"cells":2324},"Cinacalcet",{"EARLY_PHASE1":2325,"PHASE1":2327,"PHASE2":2329,"PHASE3":2331,"PHASE4":2333,"NA":2335},{"trials":2326,"activeCount":98},[],{"trials":2328,"activeCount":98},[],{"trials":2330,"activeCount":98},[],{"trials":2332,"activeCount":98},[],{"trials":2334,"activeCount":98},[],{"trials":2336,"activeCount":98},[2337],{"nctId":2338,"briefTitle":2339,"status":614,"phases":2340,"primaryCompletion":2341,"completion":1708,"start":2316,"enrollment":674,"conditions":2342,"interventions":2343},"NCT02227264","Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?",[91],"2021-12",[2181],[2323],{"intervention":2345,"totalTrials":94,"cells":2346},"Dexmedetomidine",{"EARLY_PHASE1":2347,"PHASE1":2349,"PHASE2":2351,"PHASE3":2353,"PHASE4":2355,"NA":2357},{"trials":2348,"activeCount":98},[],{"trials":2350,"activeCount":98},[],{"trials":2352,"activeCount":98},[],{"trials":2354,"activeCount":98},[],{"trials":2356,"activeCount":98},[],{"trials":2358,"activeCount":98},[2359],{"nctId":2360,"briefTitle":2361,"status":614,"phases":2362,"primaryCompletion":2363,"completion":2363,"start":2364,"enrollment":2365,"conditions":2366,"interventions":2368},"NCT05163704","Dexmedetomidine Sedation in Children Before MRI Examinations",[91],"2021-06-30","2017-11-01",1091,[2367],"Deep Sedation",[2345],{"intervention":2370,"totalTrials":94,"cells":2371},"Conservative, non-surgical treatment",{"EARLY_PHASE1":2372,"PHASE1":2374,"PHASE2":2376,"PHASE3":2378,"PHASE4":2380,"NA":2382},{"trials":2373,"activeCount":98},[],{"trials":2375,"activeCount":98},[],{"trials":2377,"activeCount":98},[],{"trials":2379,"activeCount":98},[],{"trials":2381,"activeCount":98},[],{"trials":2383,"activeCount":98},[2384],{"nctId":2385,"briefTitle":2386,"status":614,"phases":2387,"primaryCompletion":2388,"completion":2388,"start":2222,"enrollment":2389,"conditions":2390,"interventions":2393},"NCT01572558","Conservative Treatment of Acute Appendicitis in Children",[91],"2012-10",51,[2391,2392],"Appendicitis","Child",[2370],{"intervention":2395,"totalTrials":94,"cells":2396},"leflunomide",{"EARLY_PHASE1":2397,"PHASE1":2399,"PHASE2":2401,"PHASE3":2403,"PHASE4":2405,"NA":2407},{"trials":2398,"activeCount":98},[],{"trials":2400,"activeCount":98},[],{"trials":2402,"activeCount":98},[],{"trials":2404,"activeCount":98},[],{"trials":2406,"activeCount":98},[],{"trials":2408,"activeCount":98},[2409],{"nctId":2410,"briefTitle":2411,"status":208,"phases":2412,"primaryCompletion":2413,"completion":2413,"start":673,"enrollment":2414,"conditions":2415,"interventions":2418},"NCT00684372","BK Viremia After Renal Transplantation",[91],"2009-05",100,[2416,2417],"Terminal Renal Failure","BK Virus Infection",[2395]]